Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Weight, GLP-1 & Metabolic Therapy

CoverageWeight, GLP-1 & Metabolic Therapy

Do GLP-1 drugs increase thyroid cancer risk in humans?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·11 studies analyzed·1 core study·Applies to: men with preexisting or high cardiovascular risk

Bottom line

Rodent C-cell tumor signals led to contraindications in medullary thyroid carcinoma and MEN2. Human epidemiologic data have not established a clear excess of thyroid cancer, but long-term surveillance continues.[1–6]

Evidence confidence

Evidence Confidence

Moderate
LimitedModerateHigh

Relevant evidence exists, but study designs, populations, or conclusions differ enough to keep certainty moderate.

Key uncertainty. Observational latency may not capture very long-term risk.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

Semaglutide thyroid cancer▼

Rodent C-cell tumor signals led to contraindications in medullary thyroid carcinoma and MEN2. Human epidemiologic data have not established a clear excess of thyroid cancer, but long-term surveillance continues.

GLP-1 medullary thyroid▼

Rodent C-cell tumor signals led to contraindications in medullary thyroid carcinoma and MEN2. Human epidemiologic data have not established a clear excess of thyroid cancer, but long-term surveillance continues.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 11 relevant studies.

Overall finding

1 study addresses major adverse cardiovascular events, with weighted findings showing unclear findings. 1 study addresses mortality, with weighted findings showing unclear findings. 6 studies address weight / body composition, with weighted findings showing benefit. 2 studies address hba1c / glycemic control, with weighted findings showing benefit. 4 randomized or systematic-review reports and 5 observational studies address treatment.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Unclear

Major adverse cardiovascular events

moderate · 1 study

1 study addresses major adverse cardiovascular events, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 37952131
Unclear

Mortality

moderate · 1 study

1 study addresses mortality, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 27633186
Reassuring

Weight / body composition

moderate · 6 studies

6 studies address weight / body composition, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 33567185PMID 42600634PMID 40537987PMID 42060800PMID 42588312PMID 41909366
Reassuring

HbA1c / glycemic control

limited · 2 studies

2 studies address hba1c / glycemic control, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 40537987PMID 42060800
Reassuring

Blood pressure

limited · 1 study

1 study addresses blood pressure, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 40537987
Reassuring

LDL-C

limited · 1 study

1 study addresses ldl-c, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 40537987

Magnitude / clinical importance

Validated effect estimates in the analyzed set include hazard ratio.; or 1.0; odds ratio=1.34. Statistical significance is not the same as clinical importance.

Interpret magnitude in absolute terms for the patient in front of you, not from relative estimates alone.

Agreement across studies

High-influence studies disagree on direction. Weighted interpretation, not vote counting, determines the synthesis.

Supports main conclusion: 3 · Neutral / mixed: 8 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.
  • This meta-analysis aimed to clarify the association between glucagon-like peptide-1 receptor agonists, used for weight management in obesity, and the risks of pancreatitis and pancreatic cancer.
  • Obesity and type 2 diabetes mellitus (T2DM) are widespread health concerns that often coexist, contributing to increased cardiometabolic risks and premature death.

Risks & harms

5 studies report safety-relevant findings. Design mix: Study design not clearly classified, Randomized controlled trial, Narrative review, Expert opinion / editorial. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

The evidence set is heterogeneous. The most recurrent population is men with preexisting or high cardiovascular risk, but several distinct groups were studied.

What remains uncertain

  • Observational latency may not capture very long-term risk.
  • Observational latency may not capture very long-term risk.
  • Surrogate improvement does not prove a hard clinical outcome.

Clinical takeaway

Avoid GLP-1 agonists in medullary thyroid carcinoma and MEN2 per labeling. In other patients, counsel on rodent signal versus human data while maintaining routine thyroid surveillance as clinically indicated.

Unclear

Major adverse cardiovascular events?

Unclear findings

moderate[37952131]

Unclear

Mortality?

Unclear findings

moderate[27633186]

Reassuring

Weight / body composition?

Benefit

moderate[33567185 · 42600634 · 40537987 · 42060800 · 42588312 · 41909366]

Reassuring

HbA1c / glycemic control?

Benefit

limited[40537987 · 42060800]

Reassuring

Blood pressure?

Benefit

limited[40537987]

Reassuring

LDL-C?

Benefit

limited[40537987]

Unclear

Bone mineral density?

Unclear findings

limited[42588312]

4 randomized or systematic-review reports and 5 observational studies address treatment. Weighted treatment findings show mixed findings.

4 RCT / systematic review · 5 observational

Large randomized trials strongly influence the conclusion

One landmark study with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

10 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

Study quality or consistency across available evidence limits certainty.

11 analyzed studies

Strongest evidence

Supporting literature

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

+7 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Weight, GLP-1 & Metabolic Therapy.

Does GLP-1 treatment cause meaningful muscle loss?

GLP-1 therapies reduce weight through fat and lean mass loss; lean loss is partly proportional to total weight lost. Resistance training and adequate protein may mitigate but not eliminate lean mass decline.

11 linked studies

Do GLP-1 receptor agonists reduce major cardiovascular events?

GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.

14 linked studies

Do patients regain weight after stopping GLP-1 therapy?

Clinical trials and observational follow-up show substantial weight regain after GLP-1 discontinuation, suggesting chronic therapy may be needed to maintain benefit unless durable lifestyle changes are established.

11 linked studies

Do GLP-1 agonists increase pancreatitis risk?

Early signals raised pancreatitis concern, but large trials and post-marketing data have not confirmed a strong causal increase at population level. Caution remains reasonable in patients with prior pancreatitis.

11 linked studies

Go deeper on Weight, GLP-1 & Metabolic Therapy

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Weight, GLP-1 & Metabolic TherapyView pricing